Toboroz
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305· 3. fázis· AstraZeneca· Forrás
Contact: AstraZeneca Clinical AstraZeneca Clinical
Toboroz
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
NCT07069829· AstraZeneca· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581· 2. fázis· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738· 2. fázis· AstraZeneca· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884· 2. fázis· Endeavor Biomedicines, Inc.· Forrás
Toboroz
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
NCT06314282· AstraZeneca· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449· 3. fázis· AstraZeneca· Forrás
Toboroz
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864· 3. fázis· AstraZeneca· Forrás
Contact: AstraZeneca Breast Cancer Study Locator Service
Fut, nem toboroz
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
NCT05817110· AstraZeneca· Forrás
Fut, nem toboroz
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
NCT03706690· 3. fázis· AstraZeneca· Forrás
Toboroz
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
NCT03549754· AstraZeneca· Forrás
Fut, nem toboroz
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840· 3. fázis· Acerta Pharma BV· Forrás
Fut, nem toboroz
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437· 3. fázis· AstraZeneca· Forrás